• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

HTX Urology set to participate in study for Urotronic’s prostate treatment device

March 16, 2021 By Sean Whooley

UrotronicUrotronic announced that HTX Urology is participating in an FDA-cleared study for a minimally invasive device for treating enlarged prostates.

Plymouth, Minn.-based Urotronic’s Optilume BPH (benign prostatic hyperplasia, otherwise known as enlarged prostate) catheter system is an outpatient procedure designed to combine balloon dilation to open the prostate and local drug delivery to maintain symptom relief. In contrast to other BPH procedures, there is no cutting, burning, steaming or use of lasers as nothing is left behind in the prostate, according to a news release.

Dr. R. Robert Dhir of HTX Urology in Webster, Texas, is set to use the Optilume BPH catheter system after a previous clinical study of 80 men who suffered from moderate-to-severe lower urinary tract symptoms caused by BPH found that patient quality of life symptom scores improved by more than 60% at the three-month mark and were sustained through two-year follow-up.

Investigators for the study with HTX Urology will monitor the progress of the current clinical trial, titled “Pinnacle,” which is now enrolling patients and following them for five years. The FDA is monitoring the progress of the trial for the investigational device as well.

“This is a promising solution for many of our patients,” Dhir said in the release. “They will benefit tremendously from its convenience and the fact it’s minimally invasive. There’s no other treatment option like it out there right now.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured Tagged With: HTX Urology, urotronic

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS